Explore 3 Stock Ideas & Industry Insights Download Free Report

Broncus Holding Corporation

Healthcare US BRNHF

0.08USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

Day Range

0.080.08
LowHigh

52 Week Range

0.080.31
LowHigh

Fundamentals

  • Previous Close 0.08
  • Market Cap42.13M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.73700M
  • Revenue TTM0.17M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.91700M
  • Diluted EPS TTM-0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -15.30000M -28.08900M -28.03300M -236.17500M -48.78400M
Minority interest 0.00000M 0.00100M 0.00000M 0.39M 0.55M
Net income -15.30300M -28.09100M -28.03600M -235.78400M -48.23700M
Selling general administrative 7.26M 8.93M 20.42M 31.25M 10.38M
Selling and marketing expenses 8.49M 11.49M - - -
Gross profit 6.14M 7.23M 7.32M 8.74M 2.51M
Reconciled depreciation 3.21M 2.87M 2.85M 2.69M 2.19M
Ebit -15.21600M -27.92600M - -39.85300M -21.13500M
Ebitda -12.00500M -25.05330M -25.08700M -233.31400M -45.94500M
Depreciation and amortization 3.21M 2.87M - - -
Non operating income net other - - - - -
Operating income -19.79100M -33.22100M -31.77300M -37.42900M -20.56900M
Other operating expenses 27.92M 43.58M - - -
Interest expense 0.08M 0.10M 0.10M 0.17M 0.65M
Tax provision 0.00300M 0.00300M 0.00300M 0.00300M 0.00200M
Interest income 6.53M 6.04M 2.63M 0.16M 0.08M
Net interest income 6.45M 5.88M 2.53M -0.00900M -0.57100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00300M 0.00300M 0.00300M 0.00300M 0.00200M
Total revenue 8.13M 10.26M 9.41M 10.89M 3.26M
Total operating expenses 25.93M 40.45M 41.19M 48.32M 23.83M
Cost of revenue 1.99M 3.03M 2.10M 2.15M 0.75M
Total other income expense net 4.49M 5.13M - - -
Discontinued operations - - - - -
Net income from continuing ops -15.30300M -28.09200M -28.03600M -236.17800M -48.78600M
Net income applicable to common shares - - -28.03600M -235.78400M -48.23700M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 175.90M 195.81M 221.94M 252.81M 39.88M
Intangible assets 7.71M 8.97M 5.91M 7.04M 8.26M
Earning assets - - - - -
Other current assets 1.22M 1.10M 0.00100M 0.84M 1.28M
Total liab 6.42M 10.44M 8.48M 10.39M 162.32M
Total stockholder equity 169.48M 185.37M 213.46M 242.42M -120.51300M
Deferred long term liab - - - - -
Other current liab 5.78M 7.36M - 4.29M 4.06M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00600M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00600M
Retained earnings -476.57200M -461.89800M - -408.72400M -172.94000M
Other liab - - - 0.23M 0.08M
Good will - - - - -
Other assets - -0.00628M 1.81M 2.42M 0.48M
Cash 46.47M 83.56M 106.76M 227.21M 18.79M
Cash and equivalents - - - - -
Total current liabilities 6.42M 9.16M 7.42M 8.96M 14.23M
Current deferred revenue - 0.68M - - -
Net debt -46.15500M -81.20900M - - -
Short term debt 0.32M 1.13M - - -
Short long term debt 0.02M 0.02M 0.03M 0.01M 3.73M
Short long term debt total 0.32M 2.35M - - -
Other stockholder equity 646.04M 593.59M - 59.11M 52.42M
Property plant equipment - - - 4.64M 4.46M
Total current assets 151.79M 172.65M 202.87M 238.72M 26.68M
Long term investments - - - - -
Net tangible assets - - 207.55M 235.38M -128.77100M
Short term investments 92.64M 72.84M 81.15M - -
Net receivables 7.86M 9.98M 8.60M 6.13M 3.47M
Long term debt - - - 0.00000M 0.46M
Inventory 3.60M 4.71M 4.30M 4.19M 3.05M
Accounts payable 0.25M 0.40M 0.32M 0.40M 0.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 53.67M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 92.78M 0.75M - - -
Deferred long term asset charges - - - - -
Non current assets total 24.11M 23.15M 19.08M 14.09M 13.20M
Capital lease obligations 0.30M 2.34M 1.44M 1.94M 1.93M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -25.91000M 5.49M -87.56900M -1.75300M -1.08900M
Change to liabilities - - 0.00000M -0.12700M 0.10M
Total cashflows from investing activities -25.91000M 5.49M -87.56900M -1.75300M -1.08900M
Net borrowings 0.00600M -0.72000M - -3.68100M -4.62900M
Total cash from financing activities -1.02500M -1.45900M - 241.82M 32.23M
Change to operating activities - - - 0.53M 1.94M
Net income -15.30000M -28.08900M -28.03600M -235.78400M -48.23700M
Change in cash -37.09100M -23.19200M -119.09500M 208.42M 15.70M
Begin period cash flow 83.56M 106.76M 227.21M 18.79M 3.08M
End period cash flow 46.47M 83.56M 106.76M 227.21M 18.79M
Total cash from operating activities -10.00200M -26.13200M -30.95400M -31.49400M -15.58800M
Issuance of capital stock 0.00000M 0.06M 0.12M 253.90M 37.63M
Depreciation 3.21M 2.87M 2.85M 2.68M 2.18M
Other cashflows from investing activities 0.01M 0.17M - - 0.09M
Dividends paid - - - - -
Change to inventory 1.06M -0.49200M -0.10600M -1.15100M -1.23400M
Change to account receivables 0.74M 0.18M - -4.96400M 1.02M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities -1.03100M -0.79400M - -8.39600M -0.76600M
Change to netincome - - - 207.31M 28.64M
Capital expenditures 0.32M 0.70M 0.86M 1.85M 1.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.98M -0.62100M -4.67400M -5.71200M 1.81M
Stock based compensation 0.24M 0.56M 1.12M 9.01M 0.51M
Other non cash items 0.87M -0.85070M -2.53000M 197.76M 28.16M
Free cash flow -10.32400M -26.83500M -31.81000M -33.37500M -16.76200M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BRNHF
Broncus Holding Corporation
- -% 0.08 - - 242.11 0.20 0.52
ABT
Abbott Laboratories
-0.3402 0.38% 88.07 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation
-3.305 1.07% 304.50 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
-0.0699 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
-0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

Profile

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used to mark the location of the lung nodule for positioning during surgical pneumonectomy; Mist Fountain, a disposable nebulizing micro-catheter for endoscope used for airway anaesthesia, precise antibacterial and anti-inflammatory, tuberculosis drug delivery, phlegm reduction and elimination, and thoracic surgery staining location; and BroncTru, a disposable transbronchoscopic dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro System, an archimedes system. In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; BioStarNeedle, a single use ultrasound-guided needle for retrieval of tissue samples; and Steerable Sheath. The company was incorporated in 2012 and is headquartered in Hangzhou, China.

Broncus Holding Corporation

Building 8, Hangzhou, China

Key Executives

Name Title Year Born
Mr. Guowei Zhan CEO, GM & Exec. Director 1976
Mr. Hong Xu CTO & Exec. Director 1987
Mr. Todd A. Cornell Pres of Broncus Medical & Uptake Medical 1970
Thomas M. Keast VP, Operation Director & Scientist in resident NA
Feng Yao Sr. Accountant NA
Ms. Elaine Lu Director of Fin. & Admin. NA
Ms. Yin Kwan Ho Company Sec. 1977
Mr. Hong Xu Chairman of the Board & CEO 1987
Ms. Elaine Lu Director of Finance & Administration NA
Ms. Ka Yan Suen Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.